Bryce Point Capital LLC Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Bryce Point Capital LLC purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,719 shares of the biopharmaceutical company’s stock, valued at approximately $451,000.

Other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 493 shares during the period. Human Investing LLC bought a new position in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $42,000. Van ECK Associates Corp grew its holdings in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 273 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at approximately $83,000. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical in the third quarter worth $93,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 25,000 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the completion of the sale, the chief executive officer now owns 2,158,985 shares of the company’s stock, valued at $91,713,682.80. This trade represents a 1.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares in the company, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,643 shares of company stock worth $5,256,268. Insiders own 5.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on RARE. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler dropped their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a report on Monday, March 17th. Finally, Wedbush reiterated a “neutral” rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Stock Down 7.7 %

Shares of Ultragenyx Pharmaceutical stock opened at $32.43 on Friday. The stock has a market cap of $3.04 billion, a P/E ratio of -5.12 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a 12-month low of $32.07 and a 12-month high of $60.37. The business’s 50 day moving average is $40.83 and its 200-day moving average is $46.10.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. On average, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.